Pfizer’s Phase 3 clinical trial of XELJANZ in ankylosing spondylitis: A breakthrough in treatment

Pfizer has announced the successful completion of a Phase 3 clinical trial for its drug XELJANZ (tofacitinib) in adults with active ankylosing spondylitis (AS), a ... Read More